AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts

AbbVie has terminated its Alzheimer's and Parkinson’s disease pacts with Voyager Therapeutics. The Big Pharma paid $134 million to enter into the two partnerships, but then dropped the projects after Voyager completed research activities.